CN1257976C - 改良疫苗 - Google Patents

改良疫苗 Download PDF

Info

Publication number
CN1257976C
CN1257976C CNB97180897XA CN97180897A CN1257976C CN 1257976 C CN1257976 C CN 1257976C CN B97180897X A CNB97180897X A CN B97180897XA CN 97180897 A CN97180897 A CN 97180897A CN 1257976 C CN1257976 C CN 1257976C
Authority
CN
China
Prior art keywords
plasmid
cell
coding
sequence
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB97180897XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1242045A (zh
Inventor
J·J·基姆
王宾
J·D·博耶
D·B·韦纳
V·阿亚沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CN1242045A publication Critical patent/CN1242045A/zh
Application granted granted Critical
Publication of CN1257976C publication Critical patent/CN1257976C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
CNB97180897XA 1996-10-23 1997-10-23 改良疫苗 Expired - Lifetime CN1257976C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2861396P 1996-10-23 1996-10-23
US60/028,613 1996-10-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006100718690A Division CN1868545A (zh) 1996-10-23 1997-10-23 改良疫苗

Publications (2)

Publication Number Publication Date
CN1242045A CN1242045A (zh) 2000-01-19
CN1257976C true CN1257976C (zh) 2006-05-31

Family

ID=21844431

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006100718690A Pending CN1868545A (zh) 1996-10-23 1997-10-23 改良疫苗
CNB97180897XA Expired - Lifetime CN1257976C (zh) 1996-10-23 1997-10-23 改良疫苗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2006100718690A Pending CN1868545A (zh) 1996-10-23 1997-10-23 改良疫苗

Country Status (8)

Country Link
EP (1) EP0958364A4 (ja)
JP (3) JP2001507216A (ja)
KR (4) KR100780158B1 (ja)
CN (2) CN1868545A (ja)
AU (1) AU729579B2 (ja)
BR (1) BR9712852A (ja)
CA (3) CA2745736C (ja)
WO (1) WO1998017799A1 (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002301344B2 (en) * 1998-05-06 2005-01-13 Association Francais Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
WO1999056784A2 (en) * 1998-05-06 1999-11-11 Transgene S.A. Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10
CA2328059A1 (en) * 1998-05-07 1999-11-11 Akzo Nobel Nv Use of interleukin-18 as vaccine adjuvant
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
WO2000051432A1 (en) * 1999-03-03 2000-09-08 The Trustees Of The University Of Pennsylvania Vaccines and gene therapy compositions and methods of making and using the same
AU777952B2 (en) * 1999-04-23 2004-11-04 Pharmexa A/S Method for down-regulating IL5 activity
ATE516046T1 (de) 1999-05-13 2011-07-15 Wyeth Corp Adjuvans kombinationsformulierungen
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US7355092B2 (en) * 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
US7092633B2 (en) 2000-11-14 2006-08-15 University Of Texas System Board Of Regents System and method for configuring optical circuits
JP2002221520A (ja) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd 免疫型の予測方法
WO2002077210A2 (en) * 2001-03-27 2002-10-03 University Of Saskatchewan Methods to culture circovirus
KR20030012199A (ko) * 2001-07-31 2003-02-12 (주)지노첵 사이토카인 유전자를 유효성분으로 포함하는 ｄｎａ 백신
WO2003059953A2 (en) 2002-01-17 2003-07-24 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
AU2003295502A1 (en) 2002-11-12 2004-06-03 Yucheng Chang Adenoviral vector vaccine
WO2004058278A1 (en) 2002-12-16 2004-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing il-15 and methods of using the same
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005058940A2 (en) 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
EA009559B1 (ru) 2003-12-17 2008-02-28 Элан Фармасьютикелз, Инк. КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101228272A (zh) * 2005-04-20 2008-07-23 生物载体株式会社 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗
PT2041270E (pt) 2006-07-13 2013-12-27 Wyeth Llc Produção de glicoproteínas
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
MX2009009240A (es) 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
AU2009231598B2 (en) 2008-04-04 2015-03-12 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CN102370979B (zh) * 2011-10-10 2013-05-01 中国人民解放军第四军医大学 一种针对人TNF-α分子的自体疫苗的构建方法
AU2013292617A1 (en) 2012-07-19 2015-01-22 Zoetis Llc Bovine influenza C virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
MY187936A (en) 2013-03-15 2021-10-29 In3Bio Ltd Self-assembling synthetic proteins
US20160008449A1 (en) 2013-03-15 2016-01-14 Zoetis Services Llc CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
US11419925B2 (en) * 2013-03-15 2022-08-23 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
JP6675484B2 (ja) 2015-08-14 2020-04-01 ゾエティス・サービシーズ・エルエルシー マイコプラズマ・ボビス組成物
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
KR102637862B1 (ko) 2017-12-13 2024-02-19 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
KR20210094534A (ko) 2018-10-17 2021-07-29 센티 바이오사이언시스, 인코포레이티드 병용 암 면역 요법
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3897691A4 (en) * 2018-12-21 2022-08-31 The Regents of the University of California IL-10 VACCINES AND THEIR USES
CN110170049B (zh) * 2019-06-01 2023-07-04 山西农业大学 一种用于鸡球虫病活疫苗的细胞因子基因佐剂
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128621B (en) * 1982-10-11 1987-08-12 Nat Biolog Standards Board Polypeptides useful in vaccination against enteroviruses
ATE132534T1 (de) * 1986-08-01 1996-01-15 Commw Scient Ind Res Org Rekombinanter impfstoff
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5238823A (en) * 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Also Published As

Publication number Publication date
CA2745736C (en) 2016-11-22
EP0958364A1 (en) 1999-11-24
KR20050008860A (ko) 2005-01-21
JP2001507216A (ja) 2001-06-05
CN1242045A (zh) 2000-01-19
KR20000052710A (ko) 2000-08-25
AU5002297A (en) 1998-05-15
CN1868545A (zh) 2006-11-29
BR9712852A (pt) 1999-11-16
KR100780158B1 (ko) 2007-11-27
KR20050053796A (ko) 2005-06-08
CA2751712A1 (en) 1998-04-30
AU729579B2 (en) 2001-02-01
KR100629835B1 (ko) 2006-09-29
CA2751712C (en) 2016-11-22
EP0958364A4 (en) 2001-10-31
JP2009232860A (ja) 2009-10-15
KR20070108418A (ko) 2007-11-09
JP2008194046A (ja) 2008-08-28
CA2269074A1 (en) 1998-04-30
WO1998017799A1 (en) 1998-04-30
CA2745736A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
CN1257976C (zh) 改良疫苗
CN1291235A (zh) 疫苗、免疫治疗剂及其应用方法
Kim et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
CN1183968C (zh) 改良疫苗
CN1196495C (zh) 突变的人cd80及其制备和应用组合物和方法
CN1446102A (zh) 模仿天然病毒感染并诱导对病原体的持久免疫力的遗传疫苗
CN1283121A (zh) 用于预防和治疗接种的hiv－1tat或其衍生物
CN1216064A (zh) 合成的hiv基因
WO1998017799A9 (en) Immunotherapy and improved vaccines
CN1832956A (zh) 编码IgE信号肽和/或IL－15的核酸序列与包含IgE信号肽和/或IL－15的组合物及其使用方法
CN1171814A (zh) 多核苷酸结核病疫苗
CN1659187A (zh) 融合铁蛋白在疫苗和其他方面的应用
CN1764474A (zh) 免疫原性组合物及方法
JP4180826B2 (ja) ＩＬ−１２活性を増加させるＩＬ−１２ｐ４０小単位体突然変異遺伝子及びこれをＤＮＡワクチン免疫増強剤として利用する用途
JP2003526360A6 (ja) ＩＬ−１２活性を増加させるＩＬ−１２ｐ４０小単位体突然変異遺伝子及びこれをＤＮＡワクチン免疫増強剤として利用する用途
CN1812810A (zh) 针对fiv感染的免疫接种材料和方法
CN1287850C (zh) 疫苗、免疫治疗剂及它们的使用方法
CN1529758A (zh) 新的表达载体及其应用
CN1636013A (zh) 可编码hiv辅助蛋白的dna疫苗
CN1054613A (zh) 一种在预防和治疗人体逆转录病毒中作为抗病毒剂和免疫原的非复制性的重组逆转录病毒颗粒
CN1840659A (zh) 治疗内毒素血症的方法
CN101076247A (zh) Hiv－感染个体的治疗性免疫
CN1225132A (zh) Hiv包膜多肽和疫苗
CN1920041A (zh) HIV－1中国流行株gag基因的改造及其重组DNA疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Free format text: FORMER NAME: THE TRUSTEES OF THE PENNSYLVANIA STATE UNIVERSITY

CP01 Change in the name or title of a patent holder

Address after: American Pennsylvania

Patentee after: The Trustees of the University of Pennsylvania

Address before: American Pennsylvania

Patentee before: The Trustees of The University of Pennsylvania

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20060531